Metabolic reprogramming rewires aberrant immune responses to drive endothelial dysfunction in Kawasaki disease: a narrative review Authors: Zixuan Zhao, Shuhui Wang, Xuan Li, Liyan Zhu, Haitao Lv, Guanghui Qian Published: 2026 ABSTRACT AbstractBackground and ObjectiveKawasaki disease (KD) is a systemic pediatric vasculitis characterized by dysregulated immune activation and substantial risk of coronary artery lesions. Emerging evidence suggests metabolic reprogramming is a critical link between immune responses and endothelial dysfunction during KD progression. This review aims to provide an integrated overview of metabolic alterations in KD pathogenesis, focusing on clinical observations, mechanistic insights, and experimental evidence.MethodsA literature search was conducted using PubMed and Web of Science to identify studies published up to July 2026, combining “Kawasaki disease” with terms related to metabolism and metabolic pathways, including metabolites, glucose, glycolysis, amino acids, lipids, fatty acid oxidation, succinic acid, the tricarboxylic acid (TCA) cycle, nitric oxide, urine, gut microbiota, mouse models, and therapeutic strategies. Relevant clinical, experimental, and mechanistic studies were reviewed and synthesized.Key Content and FindingsAccumulating evidence indicates extensive metabolic remodeling in KD, including enhanced glycolysis, disrupted lipid metabolism and fatty acid oxidation, altered amino acid metabolism, and TCA cycle perturbations. These abnormalities are closely linked to immune activation, mitochondrial dysfunction, oxidative stress, and vascular inflammation. KD mouse models further support metabolic reprogramming, marked by altered tryptophan and amino acid metabolism, lipid metabolism, and lactate production. Notably, kynurenine pathway activation with reduced tryptophan availability is associated with inflammatory amplification and mitochondrial impairment. Beyond host-derived changes, gut microbiota dysbiosis and its metabolites appear to correlate with immune responses and disease severity. However, clinical translation of these metabolic signatures into reliable biomarkers or therapeutic targets remains limited.ConclusionsThis review highlights metabolic reprogramming as a key interface linking immune dysregulation, endothelial injury, and vascular complications in KD. Metabolic abnormalities may act not merely as consequences of inflammation but as active regulators of vascular dysfunction and disease progression. Significant gaps remain in establishing causal relationships between specific metabolic alterations and KD pathogenesis. Future studies integrating multicenter cohorts with cellular, multi-omics, and animal model approaches, particularly centered on the metabolic-immune-vascular injury axis, will be essential for identifying novel biomarkers and therapeutic strategies.Keywords: Kawasaki disease (KD), metabolism, immune response, endothelial dysfunction Introduction Kawasaki disease (KD) is an acute, self-limited systemic vasculitis predominantly affecting infants and young children, and remains the leading cause of acquired heart disease in developed countries (1). Although intravenous immunoglobulin (IVIG) therapy substantially alleviates acute symptoms and reduces the risk of coronary artery lesions (CALs), 10–20% of patients do not respond to initial treatment and thus face an elevated risk of CALs (2-5). Despite decades of clinical and experimental investigation into genetic and environmental risk factors (6,7), the precise etiology of KD remains incompletely understood (8). Both our work and previous studies suggest that an aberrant immune response, likely triggered by certain unknown pathogens, might be the key driver contributing to KD pathogenesis (9), which is often characterized by the activation and infiltration of both innate and adaptive immune cells into the coronary artery wall (8). More specifically, early pathological reports from fatal KD cases proposed a sequential model of vasculopathy, beginning with neutrophilic infiltration of the coronary arteries, followed by infiltration or replacement by mononuclear cells (10,11). In addition to neutrophils (12), monocytes and macrophages (13), activated CD8+ T cells (14) were identified as the key cells present within the arterial wall and to contribute to the active remodeling of coronary arterial lesions in KD (15). These cells together secrete substantial amounts of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-1β, thereby aggravating the inflammatory and metabolic responses of both immune cells and endothelial cells. Emerging immunometabolism studies have demonstrated that immune cell function is intricately linked to cellular metabolic states (16). Upon activation, immune cells undergo profound metabolic reprogramming to meet the energetic and biosynthetic demands required for proliferation, cytokine secretion, and effector functions; the resulting metabolites function as either byproducts of immune activation or active drivers of inflammatory responses (17). Importantly, KD patients undergo profound metabolic remodeling that accompanies, and potentially regulates, the inflammatory response. These metabolic adaptations, including glycolysis, mitochondrial oxidative phosphorylation, fatty acid metabolism, amino acid utilization, and redox homeostasis, provide the metabolic foundation required for immune activation and effector functions. In line with these observations, serum- and plasma-based metabolomic studies have identified alterations in amino acid, lipid, and energy metabolism during KD pathogenesis, suggesting that metabolic reprogramming may represent a critical link between immune dysregulation and vascular injury. A comprehensive understanding of the molecular and cellular mechanisms linking metabolic rewiring to immune dysregulation and vascular pathology will not only deepen our understanding of KD pathogenesis but also facilitate the identification of novel biomarkers and the development of metabolism-based therapeutic strategies to prevent coronary artery complications. Nevertheless, it remains controversial whether metabolic reprogramming is merely a consequence of inflammation or also a central regulator of aberrant immune activation and endothelial dysfunction in KD, and the precise relationships among metabolic alterations, immune dysregulation, and vascular injury remain incompletely understood. In this review, we provide a comprehensive, mechanism-oriented synthesis of recent findings on metabolic dysregulation in KD and its contribution to disease pathogenesis. We highlight key metabolic pathways and metabolites involved in shaping aberrant immune responses, endothelial dysfunction, and vascular remodeling during KD progression in both patients and experimental models. Additionally, we discuss emerging insights into the translational potential of targeting metabolic pathways as an adjunctive therapeutic approach alongside standard KD treatments. Future investigations employing novel metabolic modulators to reshape immune cell phenotypes, restore metabolic homeostasis, and attenuate inflammatory responses may offer promising strategies to prevent coronary artery remodeling and reduce vascular injury in children with KD. We present this article in accordance with the Narrative Review reporting checklist (available at https://tp.amegroups.com/article/view/10.21037/tp-2026-0494/rc). Methods This article was designed as a narrative review. We searched PubMed and Web of Science databases for English-language literature published between July 1979 and July 2026, using combinations of the term “Kawasaki disease (KD)” with the following keywords respectively: metabolism, metabolites, glucose, glycolysis, amino acids, lipids, fatty acid oxidation, succinic acid, tricarboxylic acid (TCA) cycle, nitric oxide, urine, gut microbiota, mouse model, and therapeutic strategy. Reference lists of relevant reviews and mechanistic studies were also manually screened. The narrative literature search and selection process is summarized in Table 1. Table 1Summary of the literature search strategyItemsSpecificationDate of searchInitial search: August 27, 2025; updated: July 15, 2026Databases and other sources searchedPubMed, Web of Science, and reference lists of relevant review and mechanistic articlesSearch terms usedKawasaki disease (KD), metabolism, metabolites, glucose, glycolysis, amino acids, lipids, fatty acid oxidation, succinic acid, tricarboxylic acid (TCA) cycle, nitric oxide, urine, gut microbiota, mouse model, and therapeutic strategyTimeframeJuly 1, 1979–July 15, 2026Inclusion and exclusion criteriaInclusion criteria: studies involving the metabolites in Kawasaki disease, host-microbe metabolic interactions in KD, and targeting metabolites as a therapeutic strategy; language is restricted to English papersExclusion criteria: studies unrelated to the metabolites in KD; abstracts lacking sufficient methodological details; duplicate reports; and articles for which full text is unavailable Selection processThe search outcomes were meticulously scrutinized by two authors (Z.Z. and L.Z.), adhering strictly to the predefined inclusion and exclusion criteria. In cases where discrepancies arose, a third reviewer (G.Q.) provided an impartial decision. All authors approved the final list of references Summary of the literature search strategy Overview of abnormal immune responses in KD Although the precise etiology of KD remains elusive, dysregulated innate and adaptive immune responses are recognized as central drivers of vascular inflammation and coronary artery injury (9). Among these coordinated immune responses, innate immune activation represents a hallmark of early KD. Activated neutrophils contribute to endothelial injury through the release of reactive oxygen species (ROS), proteolytic enzymes, and neutrophil extracellular traps (NETs), which have been implicated in vascular damage and thrombosis (12). In parallel, Th17-derived IL-17 promotes neutrophil recruitment and endothelial activation (12), and monocytes/macrophages are also activated in KD (18), adopting a pro-inflammatory phenotype characterized by increased production of TNF-α, IL-1β, and IL-6. These cells infiltrate vascular tissues and further sustain vascular inflammation and extracellular matrix degradation. In addition, adaptive immune dysregulation, characterized by enhanced Th1 and Th17 responses and impaired regulatory T cell (Treg) function, constitutes a critical feature of the late phase of KD (14,19). The imbalance of CD4+ T cell subsets promotes a sustained pro-inflammatory environment that perpetuates vascular injury, whereas reduced Treg activity may compromise immune tolerance and the resolution of inflammation. Also, B lymphocyte activation and immunoglobulin production are likewise implicated in the vascular inflammatory manifestations of KD, although their precise pathogenic roles remain ambiguous (20). Importantly, both innate and adaptive immune cells described above can secrete a broad spectrum of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, IL-8, IL-33, and IFN-γ, collectively driving a cytokine storm that is closely associated with endothelial dysfunction and coronary artery inflammation (19,21,22). These elevated circulating cytokines activate endothelial cells, upregulate adhesion molecules such as ICAM-1 and VCAM-1, and enhance leukocyte recruitment into the vascular wall, thereby exacerbating vasculitis in KD. Immune activation facilitates a metabolic shift toward glycolysis in KD Glucose metabolism encompasses a sequence of events, including digestion, absorption, transport, and utilization of glycans, as well as intracellular pathways such as glycolysis, glycogen synthesis and breakdown, and the pentose phosphate pathway. Accumulating evidence indicates that acute KD is associated with increased glycolytic activity in circulating leukocytes. As illustrated in Figure 1A, immune activation in KD drives a metabolic shift toward glycolysis, characterized by increased expression levels of glucose transporter 1 (Glut1), hexokinase 2 (HK2), and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) (23), leading to increased glucose uptake, glycolytic flux, pyruvate production, and lactate accumulation. RNA-seq profiling of peripheral blood mononuclear cells (PBMCs) revealed significantly upregulated expression of genes encoding Glut1, HK2, PFKFB3, and lactate dehydrogenase A (LDHA) (Table 2) (23). These genes further promote, respectively: increased glucose uptake; phosphorylation of glucose to glucose-6-phosphate (G6P); production of fructose-2,6-bisphosphate (a potent activator of PFK1); and conversion of pyruvate to lactate, with concomitant NAD+ regeneration from NADH to sustain glycolysis. These processes may collectively lead to elevated levels of lactate, pyruvate, and other glycolytic intermediates in the serum of acute KD patients (24). Consequently, these findings together suggest that immune activation during acute KD favors a metabolic shift toward glycolysis. (A) Schematic illustration of glycolytic flux and metabolite transport, including abnormal glucose metabolism and oxidative phosphorylation in KD. Increased glucose uptake from serum is mediated by upregulation of the Glut1. Glucose is phosphorylated by HK2 to G6P and further metabolized through glycolysis, with key regulatory steps including PFKFB3 and PK. The resulting pyruvate is converted to lactate, which is exported via monocarboxylate transporters. Alternatively, pyruvate is transported into mitochondria via the mitochondrial pyruvate carrier and converted to acetyl-CoA by the PDH complex. Red arrows indicate increased levels or activity of metabolites and transporters. Purple text denotes key glycolytic enzymes. (B) Schematic illustration of impaired mitochondrial metabolism and anaplerotic pathways. Pyruvate derived from glycolysis enters the mitochondria and is converted to acetyl-CoA by the PDH complex, whose activity is negatively regulated by PDK. Acetyl-CoA fuels the TCA cycle, leading to impaired OXPHOS and NADH production. BCAAs (leucine, isoleucine, and valine) and glutamine provide additional carbon sources to replenish TCA cycle intermediates through α-KG and succinyl-CoA, respectively. Fatty acid oxidation also contributes acetyl-CoA to support mitochondrial energy metabolism. The MAS facilitates the transfer of reducing equivalents between the cytosol and mitochondria, promoting NADH generation and sustaining OXPHOS. IDH and SCS are highlighted as key enzymes regulating TCA cycle flux. Red arrows indicate increased metabolic activity, whereas purple text denotes key metabolic enzymes. BCAAs, branched-chain amino acids; G6P, glucose-6-phosphate; Glut1, glucose transporter 1; HK2, hexokinase 2; IDH, isocitrate dehydrogenase; KD, Kawasaki disease; MAS, malate-aspartate shuttle; OXPHOS, oxidative phosphorylation; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; PK, pyruvate kinase; SCS, succinyl-CoA synthetase; TCA, tricarboxylic acid; α-KG, α-ketoglutarate. Table 2Overview of metabolic alterations in KD patientsSources & metabolitesFunctional roles in KDReferenceSerum or plasma Increased lipoperoxide and decreased zinc levels Responsible for oxygen intermediates in connective tissue degradation and pathogenesis of artery abnormalities(1) Increased lactate and lactate dehydrogenaseAssociated with lactylation and inflammatory responses(24) Increased succinic acid and hyaluronic acid Linked with an increased inflammatory response and CAL development(25) Decreased methionineNegatively correlated with CRP levels and suggested as a biomarker for KD patients with IVIG sensitivity(26) Decreased low-density lipoprotein-cholesterol levelAssociated with gallbladder distension (27) Increased triglyceride and decreased levels of high-density lipoprotein and total cholesterol Decreased HDL cholesterol level associated with coronary artery lesions(28) Increased triglycerides and reduction of apoA-I, apoA-II, HDLAssociated with endothelial cell dysfunction(29) LPC and LPE decreased after IVIG treatment in the IVIG-resistant groupIdentified as markers of IVIG resistance in pretreatment diagnosis and associated with inflammatory response (30) Increased chemerin but decreased omentin-1 and adiponectin levels Associated with inflammation and lipid disorders (31) Increased bile acid and fatty acid levelsLinked to IVIG-responsiveness and CAL development(32) Increased carnitine levels Positively correlated with the release of inflammatory factors, and with refractoriness to IVIG treatment(33) Increased H-FABP Identified as a marker of myocardial injury (34) Increased L-kynurenine and kynurenic acid, decreased Trp and indole acetic acidBoth increased kynurenine and decreased Trp and indole acetic acid contribute to inflammation (35) Increased glucocorticoid secretion, cortisol levels, and the cortisol/cortisone ratio in KD before IVIG Associated with inflammatory response(36) Increased TG level Increases hypercoagulation and the risk of cardiovascular injuries(37) Increased oxidative stress and decreased NO Promotes vascular inflammation and arteriosclerotic changes(38)Urinary Increased level of U-LDH1/U-LDH2 isozymes, and total U-LDH activity in acute phase but decreased in the recovery phase Associated with renal injury due to KD vasculitis(39) Dysbiosis Reduced production of SCFAsCaused an imbalance between T helper 17 cells and Tregs(40) PBMC Decreased gene expression level of HK3, ALAS2, FACL2/ACSL2, BLVRB and SAT1HK3 is associated with the production of NLRP3, IL-1β and TNF-α(23)Reduced FACL2/ACSL2 activity prevents the efficient conversion of free fatty acids into acyl-CoADownregulation of BLVRB compromises the antioxidant defense barrier, thereby promoting vasculitis and endothelial injuryDecreased SAT1 causes metabolic disorders and persistent inflammationHUVECs Increased levels of ALDH1A1 and nitric oxide synthase 3 genes in HUVECs after stimulation with sera from KD patients treated with atorvastatinALDH1A1 enzyme prevents endothelial injury(41)CAL, coronary artery lesion; CRP, C-reactive protein; HDL, high-density lipoprotein; H-FABP, heart-type fatty acid-binding protein; HUVECs, human umbilical vein endothelial cells; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; NO, nitric oxide; PBMC, peripheral blood mononuclear cell; SCFAs, short-chain fatty acids; TG, triglyceride; TNF, tumor necrosis factor; Trp, tryptophan; U-LDH, urinary lactate dehydrogenase. Overview of metabolic alterations in KD patients CAL, coronary artery lesion; CRP, C-reactive protein; HDL, high-density lipoprotein; H-FABP, heart-type fatty acid-binding protein; HUVECs, human umbilical vein endothelial cells; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; NO, nitric oxide; PBMC, peripheral blood mononuclear cell; SCFAs, short-chain fatty acids; TG, triglyceride; TNF, tumor necrosis factor; Trp, tryptophan; U-LDH, urinary lactate dehydrogenase. Abnormal metabolism of amino acids and organic acid derivatives Emerging evidence indicates that amino acids are indispensable regulators of vascular homeostasis. They contribute to the dynamic equilibrium of blood vessels by modulating endothelial cell proliferation, migration, differentiation, apoptosis, contraction, and senescence. In acute KD, serum L-arginine levels are decreased compared with healthy controls, whereas IVIG treatment markedly increases circulating levels of L-arginine and L-threonine (25) (Table 2). Similarly, our previous work demonstrated that serum L-tryptophan levels are significantly lower in KD patients than in healthy controls (25). Another study further demonstrated that KD patients exhibited reduced levels of tryptophan and indole acetic acid (IAA) but elevated serum kynurenic acid (Kyna) levels relative to controls (35) (Table 3). Tryptophan-related metabolites, including kynurenine, 5-HTP and indole further activate the aryl hydrocarbon receptor (AhR), whose expression level is increased in PBMCs from KD patients, as demonstrated by analyses of publicly available single-cell RNA-sequencing datasets. Consistently, levels of downstream tryptophan metabolites such as L-kynurenine and kynurenic acid are upregulated in the serum of KD patients and in coronary arteritis lesions of a KD mouse model (35) (Table 3). In addition to the decreased tyrosine levels in the serum of KD mice, the essential amino acid methionine is also markedly decreased in both children with KD and KD mouse models (26) (Table 3). Methionine levels negatively correlate with C-reactive protein (CRP) and are associated with DNMT1 activation, suggesting its potential utility as a biomarker for predicting IVIG responsiveness in KD patients (26). The alanine-aspartate-glutamate metabolism pathway is among the most significantly dysregulated pathways in KD patients with coronary artery aneurysms (CAAs). Concurrently, arginine biosynthesis, phenylalanine metabolism, and the phenylalanine-tyrosine-tryptophan pathway are significantly altered in IVIG-resistant patients (43). Further multi-omics investigations are warranted to validate these findings and facilitate their translation into clinical practice for KD management. Table 3Overview of metabolic alterations in KD mouse modelsMetabolitesFunctional roles in KDReferenceIncreased Kyna and Kyn levels and reduced Trp and IAA levels in the plasma of the LCWE-induced mouse modelAssociated with inflammation(35)Decreased serum methionine in the CAWS-induced mouse modelSerum methionine identified as a biomarker for KD patients with IVIG sensitivity(26)Downregulated nicotinate and nicotinamide pathways, and a decreased level of circulating nicotinamide and nicotinamide N-oxide in LCWE-induced mouse model Contribute to inflammation and the development of cardiovascular lesions in mice(42)CAWS, Candida albicans water-soluble fraction; IAA, indole acetic acid; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; Kyn, kynurenine; Kyna, kynurenic acid; LCWE, Lactobacillus casei cell wall extract; Trp, tryptophan. Overview of metabolic alterations in KD mouse models CAWS, Candida albicans water-soluble fraction; IAA, indole acetic acid; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; Kyn, kynurenine; Kyna, kynurenic acid; LCWE, Lactobacillus casei cell wall extract; Trp, tryptophan. Lipid and fatty acid oxidation disorders Beyond the aforementioned metabolic changes, lipidomic profiling has emerged as another critical dimension in KD research. For example, early-stage KD patients exhibit significantly decreased plasma levels of total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C), alongside markedly elevated triglycerides (TG) (37). Interestingly, TC levels rapidly return to normal and remain stable within 3 months of disease onset (28). HDL-C levels, however, show a gradual increase from 15.2±9.9 mg/dL during the first 10 days to 41.5±10.4 mg/dL and stabilize around 47.2±10.9 mg/dL during a 3-year follow-up (28). Another study reported that serum HDL-C levels ranged from 29.6±11.0 to 26.8±8.9 mg/dL during the first 2 weeks, then rose to 47.9±12.6 mg/dL by 6 weeks (44). Moreover, plasma levels of HDL-C, apoA-I, and apoA-II were significantly decreased in acute-phase KD patients, and the lipid composition (cholesterol, apoA-I, and apoA-II) of HDL2 was inversely correlated with TG levels (29) (Table 2). Serum low-density lipoprotein-cholesterol (LDL-C) levels were significantly decreased in patients with gallbladder distension (GBD) compared with those without GBD or with febrile controls (27) (Table 2). Interestingly, IVIG treatment not only ameliorates disturbances in serum fatty acid metabolism (45), but also increases levels of arachidonoyl PAF C-16, a lipid precursor or analog of platelet-activating factor (PAF) (25). Fatty acids are transported into cells primarily via proteins such as CD36 and fatty acid-binding proteins (FABPs), after which they are activated to fatty acyl-CoA by acyl-CoA synthetase long-chain family member 2 (ACSL2) or other ACSL isoforms. The carnitine shuttle system, comprising CPT1, CPT2 and carnitine translocase, mediates the import of acyl-CoA into mitochondria for β-oxidation. As shown in Figure 1B and Figure 2, mitochondrial fatty acid β-oxidation (FAO) is severely dysregulated in KD patients, as reflected by elevated carnitine levels, reduced ACSL2 levels, and impaired FAO. Decreased circulating levels of nicotinamide (NAM) and nicotinamide N-oxide, precursors of NAD+, in the serum of LCWE-induced mice suggest intracellular NAD+ depletion alongside elevated levels of oxidative intermediates (42). These metabolic reprogramming events may cause lipid overload, mitochondrial stress, and a metabolic shift toward glycolysis, thereby exacerbating inflammatory responses and endothelial dysfunction. Notably, methylglutarylcarnitine (C6-DC) has been identified as a prognostic biomarker for KD patients with CAA, and elevated levels of free carnitine have been consistently detected in KD patients; carnitine synthesis and transport appear to correlate positively with inflammatory factor release and IVIG resistance (33) (Table 2), although serum levels of propionylcarnitine are reduced in KD patients compared with healthy controls (25). Schematic overview of fatty acid uptake and transport, including carnitine cycle and β-oxidation pathways in KD. (A) FAs metabolism in cells. Extracellular FAs are transferred into the cytoplasm through FATPs, FABPs, and CD36. Intracellular FAs are activated by ACSL2 to generate acyl-CoA, which can either be stored in lipid droplets or transported into mitochondria via the carnitine shuttle system. Within mitochondria, acyl-CoA undergoes β-oxidation through the sequential steps of VLCAD, LCAD, MCAD, SCAD, ECH, HADH, and β-ketothiolase, ultimately generating acetyl-CoA. The acetyl-CoA enters the TCA cycle for energy production. Red arrows indicate upregulated pathways or molecules, whereas green arrows indicate downregulated pathways or molecules. (B) The mitochondrial carnitine shuttle system. Long-chain acyl-CoA is converted to acyl-carnitine by CPT1 on the outer mitochondrial membrane. Acyl-carnitine is then translocated across the inner mitochondrial membrane by carnitine-acylcarnitine translocase and reconverted to acyl-CoA, catalyzed by CPT2 in the mitochondrial matrix, enabling entry into the β-oxidation pathway. The red arrow denotes increased carnitine availability or enhanced transport activity. In patients with KD, serum H-FABP levels are significantly higher during the acute phase than in the recovery phase. Serum FC levels are elevated in children with KD, particularly in those who do not respond to IVIG. Decreased expression level of ACSL2 in PBMCs of KD patients caused a decreased expression level of acyl-CoA. Arrows indicate the direction of metabolic flux. Acc, acetyl-CoA carboxylase; Acly, ATP citrate lyase; ACSL2, acyl-CoA synthetase long-chain family member 2; Atgl, adipose triglyceride lipase; Cpt, carnitine palmitoyltransferase; CPT1, carnitine palmitoyltransferase 1; CPT2, carnitine palmitoyltransferase 2; Dgat, acyl-CoA:diacylglycerol acyltransferase; ECH, enoyl-CoA hydratase; Elovl, elongase of long-chain fatty acids family; FA, fatty acid; FABPs, fatty acid-binding proteins; FAS, fatty acid synthase; FATPs, fatty acid transport proteins; FC, free carnitine; HADH, hydroxyacyl-CoA dehydrogenase; H-FABP, heart-type fatty acid-binding protein; Hsl, hormone-sensitive lipase; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; LCAD, long-chain acyl-CoA dehydrogenase; Lpl, lipoprotein lipase; MCAD, medium-chain acyl-CoA dehydrogenase; Mgl, monoglyceride lipase; PBMCs, peripheral blood mononuclear cells; SCAD, short-chain acyl-CoA dehydrogenase; Scd, stearoyl-CoA desaturase-1; TCA, tricarboxylic acid; VLCAD, very-long-chain acyl-CoA dehydrogenase. Furthermore, fatty acid β-oxidation can be inhibited by oxidized low-density lipoprotein (oxLDL), whose plasma concentration and the expression of its receptor lectin-like-oxLDL receptor 1 (LOX-1) in PBMCs are markedly increased in KD patients, especially in those with CALs (46). Mechanistically, oxLDL is internalized via CD36-mediated endocytosis, which triggers lipid overload, mitochondrial stress, and consequent impairment of FAO. Reduced FAO further promotes oxLDL-driven inflammatory responses, inhibits PPARα/PGC-1α signaling, and shifts cellular metabolism from FAO toward glycolysis, thereby exacerbating inflammation and lipid accumulation and deposition. Additionally, several lipid species have also emerged as potential indicators of IVIG treatment response. Elevated levels of short-chain (C2, C3) and long-chain acylcarnitines (C4, C16, C16:OH, C18, C18:2, C18:2OH) are associated with IVIG-resistance (43). In contrast, levels of lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE) are significantly reduced in the serum of IVIG-resistant patients (30) (Table 2). LPC and LPE have thus been suggested as valuable biomarkers for predicting IVIG responsiveness, with potential clinical utility in guiding therapeutic decisions. Furthermore, the level of the lipid peroxidation product malondialdehyde (MDA) is increased in the plasma of acute KD patients, whereas this biochemical abnormality normalizes after immunoglobulin treatment, paralleling the resolution of clinical symptoms (1) (Table 2). This observation highlights the potential involvement of oxygen intermediates in connective tissue degradation and vascular pathology during KD, suggesting that immunoglobulin therapy likely mitigates KD progression by counteracting oxidative stress damage. Additionally, chemerin levels rise significantly in the serum during acute KD, whereas omentin-1 and adiponectin levels decline (31). These dynamic changes in adipokines form an important part of the inflammatory and metabolic imbalance network observed during the acute phase of KD. Beyond lipid disturbances, alterations in the expression of genes involved in fatty acid metabolism, including increased ANXA2, ADH5, ACTG1, HADHA, and LGALS1, and decreased CD79B, CD37, MS4A1, IGHM, and NEAT1, have been identified in KD patients through scRNA-seq analysis of dataset GSE168732 (32). Furthermore, serum levels of heart-type fatty acid-binding protein (H-FABP), a biomarker of myocardial injury, are significantly elevated in KD patients, indicating potential cardiac involvement in children with KD (34); however, these conclusions still warrant further research due to the small sample sizes, lack of external validation, and timing of sampling from a single clinical center. Evidence for increased succinate and impaired TCA cycle As a central intermediate metabolite of the TCA cycle, succinate plays a pivotal role in coordinating mitochondrial metabolism. Notably, succinate levels are elevated in the serum of patients with KD (25). Increased circulating succinate may activate its cognate receptor, succinate receptor 1 (SUCNR1), on endothelial cells, vascular smooth muscle cells, and infiltrating immune cells. Although the mechanism underlying succinate accumulation in KD remains unclear, excessive succinate can exert feedback inhibition on upstream enzymatic reactions within the TCA cycle, thereby disrupting metabolic homeostasis. As shown in Figure 1B, mitochondrial pathways converging on the TCA cycle are closely intertwined with amino acid and fatty acid metabolism, manifesting as impaired OXPHOS activity and elevated succinate levels in KD patients. Meanwhile, branched-chain amino acids (BCAAs), glutamine, and fatty acids provide alternative carbon sources to fuel the TCA cycle through anaplerotic reactions, a process functionally coupled with the malate-aspartate shuttle (MAS). In addition, elevated serum lactate levels and increased lactate dehydrogenase (LDH) activity have been reported in KD patients (24), indicating an enhanced reliance on glycolysis for pyruvate catabolism. This metabolic shift limits the availability of acetyl-CoA for entry into the TCA cycle, thereby further suppressing mitochondrial oxidative metabolism. Furthermore, several TCA cycle-related metabolites, including isocitric acid and trans-aconitate, have recently been identified as potential diagnostic biomarkers for KD (47). Alterations in bile acid and glucocorticoid metabolites Bile acids, which are hepatically synthesized from cholesterol derivatives, function as both amphipathic surfactants and systemic endocrine hormones. Clinical evidence has demonstrated a strong correlation between fasting serum total bile acids and the severity of coronary heart disease (48), and cholestasis (bile accumulation) is occasionally observed in KD, partly due to hepatic dysfunction or inflammation (49). Notably, serum bile acid levels are significantly elevated during the acute phase of KD (45). Enhanced bile acid metabolism has also been detected in monocytes and natural killer cells of KD patients, and alterations in bile acid metabolites appear to correlate with IVIG responsiveness and CAL development (32). Bile acids specifically bind to their receptors, the farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor (TGR5), both of which are highly expressed on endothelial cells and various immune cell subsets (50), suggesting that bile acid dysregulation may contribute to disease severity and therapeutic outcomes in KD. Moreover, although IVIG remains the cornerstone of KD treatment, exogenous glucocorticoids continue to play an important role in managing IVIG-resistant, high-risk, or severe cases owing to their potent anti-inflammatory and immunosuppressive effects (51). Serum cortisol levels and the cortisol/cortisone ratio increase during the acute phase before IVIG administration and subsequently decline during convalescence (36). Notably, this cortisol/cortisone ratio, which reflects the conversion between active cortisol and inactive cortisone, is regulated by 11β-hydroxysteroid dehydrogenases (11β-HSDs). Of note, 11β-HSD gene expression was upregulated in PBMCs from IVIG-responsive patients but unchanged in non-responders (52). This result suggests that elevated expression of 11β-HSDs may serve as a metabolic marker of IVIG responsiveness. In contrast, insufficient upregulation may lead to impaired glucocorticoid activation, inadequate anti-inflammatory signaling, and IVIG non-responsiveness. These findings also support glucocorticoids as a potential compensatory therapeutic option for IVIG-resistant KD. Increased nitric oxide production and altered urinary metabolism Under physiological conditions, endothelial nitric oxide synthase (eNOS) generates low, sustained levels of NO to maintain vascular homeostasis. In KD, however, accumulating evidence indicates that dysregulation of the nitric oxide system and NO-associated oxidative stress contribute to disease progression and vascular inflammation (38). Consistent with this finding, plasma nitrate levels were also elevated during the acute phase of KD (53), paralleled by increased NO release from neutrophils in the early disease stage, which subsequently declined after IVIG therapy (54,55). In addition to neutrophils, NO is also synthesized by other cell types through nitric oxide synthases, which use L-arginine and molecular oxygen as substrates. In endothelial cells, eNOS requires the essential cofactor tetrahydrobiopterin (BH4) for efficient NO production. However, excessive ROS generated during KD oxidize BH4 to its inactive form, dihydrobiopterin (BH2), leading to eNOS uncoupling and reduced NO bioavailability despite increased NOS activity (56). Instead of producing NO, uncoupled eNOS preferentially generates superoxide, thereby amplifying oxidative stress and further impairing endothelial function. Consequently, altered arginine metabolism, BH4 depletion, and eNOS uncoupling collectively disrupt NO homeostasis, contributing to endothelial dysfunction, oxidative stress, dysregulated vascular tone, and coronary artery injury in KD. Nevertheless, the precise mechanisms by which dysregulated NO signaling drives endothelial dysfunction and coronary artery pathology in KD remain incompletely understood. Children with KD have been reported to excrete significantly higher levels of urinary nitrite/nitrate and neopterin compared with healthy controls, and these abnormalities occur more frequently than in children with other inflammatory diseases (57,58). Notably, expression of the nitric oxide synthase 3 gene is increased in human umbilical vein endothelial cells (HUVECs) following stimulation with sera from KD patients receiving atorvastatin therapy (41). Regarding total urinary lactate dehydrogenase (U-LDH) activity, levels were found to increase during the acute phase of KD, then decline in both the subacute and convalescent phases, with a predominance of the U-LDH1 and U-LDH2 isoforms (39). Together, these findings suggest that urinary biomarkers, including NO-related metabolites and U-LDH, might reflect systemic immune activation in KD. Further investigation into NO metabolism and urinary biomarkers in KD is warranted to clarify disease pathophysiology and support the development of novel therapeutic strategies. The host-microbe metabolic interactions in KD Emerging evidence suggests that gut microbial imbalance and metabolic disruption may act as a potential driver of KD, potentially via interactions with host genetics and immune pathways (59,60). For example, gut microbiota can modulate the gut-vascular axis, including decreased Anaerostipes, Subdoligranulum, Roseburia, and Lachnospira, which are associated with CALs (61). Moreover, linear discriminant analysis effect size (LEfSe) analysis also showed enrichment of Coprobacillus, Paludicola, Lautropia, UCG-009, Acetanaerobacterium, Methylobacterium-Methylorubrum, and Alistipes in KD patients with CALs (61). In particular, a higher number of Gram-positive cocci (of the genera Streptococcus and Staphylococcus), Eubacterium, Peptostreptococcus, and HSP60-producing Gram-negative microbes have been found in the stools of KD children, and they are suggested to be involved in the antigenic repertoire of specific T cells and Vβ2 T cell expansion (62). Regarding fecal metabolomic profiling in KD children, increased levels of indole, L-tryptophan, L-lactic acid, 5-HETE, indol-3-acetamid, tetraethylammonium, and dopaquinone were identified, whereas butyrate, methylxanthine, phosphocholine, methylhistidine, ADP-ribose, vitamin A acid, and chenodeoxycholic acid were decreased (63). In plasma, cholesterol, phosphocholine, porphobilinogen, pantothenate, cortisol, bile acids and related compounds were enriched in KD patients, while amino acids, indole and tryptamine derivatives, nucleotides and nucleic acids, and sugar metabolites were more abundant in healthy controls (63). Concurrently, disrupted fecal bacterial communities in KD patients were often characterized by the overgrowth of pathogenic bacteria and a marked reduction in short-chain fatty acid (SCFA)-producing species (64). Furthermore, taxa with potential SCFA-linked protective functions exhibited decreased abundance, including Bacteroidota, Bacteroides, Roseburia, Faecalibacterium, Blautia, Dialister, Lachnospira, and Prevotella, while opportunistic pathogens such as Enterococcus were enriched in acute-phase KD cohorts (65). The decreased SCFAs further lead to an imbalance between T helper 17 cells (Th17s) and regulatory T cells (Tregs), thereby propagating aberrant immune activation central to KD pathogenesis (40). Moreover, microbial-derived metabolites, including SCFAs, indole derivatives, and bile acid metabolites, may directly influence endothelial function through regulation of oxidative stress, vascular inflammation, and immune-mediated vascular injury. Altogether, these findings highlight the microbiota-immune axis as a potential therapeutic target for modulating KD progression, with interventions such as probiotic supplementation or dietary fiber enrichment, which might offer novel strategies to restore microbial homeostasis and attenuate systemic vasculitis.​ The therapeutic potential and translational challenges of targeting metabolism in KD Although high-dose IVIG plus aspirin remains the standard therapy for suppressing inflammation and preventing CALs in KD, these interventions nevertheless fail to address the full spectrum of disease pathology (66). This therapeutic gap therefore calls for the development of novel pharmacological approaches, grounded in a deeper understanding of the as-yet-elusive mechanisms and molecular drivers of the disease. Targeting metabolic pathways has emerged as a promising direction, encompassing both the identification of diagnostic metabolic markers and the development of metabolism-based therapeutic approaches. More specifically, several candidate metabolic interventions have been reported. First, N-acetylcysteine (NAC) has been investigated for its potential to reduce inflammation in KD by regulating ROS production and the NLRP3 inflammasome pathway (67). Second, the discovery of the natural compound kushenol C (KC) as a modulator of OGG1 activity offers a novel therapeutic avenue to mitigate oxidative stress and vascular injury associated with KD (68). Third, the metabolites dimethyl itaconate (DI) and dimethyl fumarate (DMF) have been suggested as potential treatments for IVIG-resistant KD, owing to their ability to suppress IL-1β- and TNFα-mediated inflammatory responses in human coronary artery endothelial cells (69). Given the pronounced alterations in the kynurenine pathway of tryptophan metabolism observed in KD, targeting this pathway represents another promising avenue for future drug development. Nevertheless, several major challenges continue to hinder clinical translation, including a limited understanding of disease-specific metabolic mechanisms, a lack of validated metabolic biomarkers and therapeutic targets, patient heterogeneity, safety concerns, and a scarcity of well-designed multicenter clinical studies. Future studies should prioritize elucidating the molecular mechanisms underlying kynurenine pathway dysregulation, validating clinically relevant metabolic biomarkers and therapeutic targets, and integrating multi-omics approaches with longitudinal clinical trials to enable patient stratification and the development of precision, metabolism-based therapies for KD. Conclusions In summary, KD is a systemic vasculitis characterized by profound immune dysregulation and a high risk of coronary artery complications. Metabolic reprogramming represents a critical interface connecting aberrant immune responses with endothelial dysfunction in KD. Alterations in glucose metabolism, lipid metabolism, amino acid utilization, mitochondrial function, and redox homeostasis have been identified in patients with KD, highlighting the close relationship between metabolic remodeling and aberrant immune responses. These metabolic disturbances, in turn, can affect the activation, differentiation, and effector functions of immune cells, thereby amplifying inflammatory responses and contributing to endothelial dysfunction and coronary artery damage in KD. Nevertheless, despite these remarkable advances, several critical knowledge gaps remain. For example, most current studies rely on serum or plasma metabolomic analyses, and metabolic alterations within coronary artery tissues and vascular microenvironments during different stages of KD remain poorly characterized owing to the limited availability of patient tissue samples. Moreover, the spatial and temporal dynamics of metabolic remodeling in affected vascular tissues remain largely unknown, and the metabolic mechanisms operating in experimental KD models have received comparatively limited attention, further restricting our ability to establish causal links between metabolic abnormalities and disease pathogenesis. Future studies from multiple centers integrating metabolomics with single-cell transcriptomics, spatial omics, proteomics, and functional metabolic analyses might comprehensively define cell-type-specific metabolic programs in immune cells, endothelial cells, and vascular smooth muscle cells during KD progression. Particular attention should be directed toward elucidating how metabolic reprogramming regulates immune cell fate decisions, inflammatory signaling pathways, and endothelial integrity. Importantly, distinguishing protective metabolic adaptations from pathogenic metabolic alterations will be essential for identifying key metabolites and pathways that either drive or restrain disease progression in KD. Furthermore, mechanistic investigations are needed to determine how specific metabolites function as signaling regulators or as donor molecules for protein post-translational modifications involved in immune responses and vascular injury. Such studies may help uncover novel mechanisms or biomarkers for disease diagnosis, risk stratification, and therapeutic monitoring in KD. In addition, further metabolic research of KD patient samples from different centers, together with validation of the related mechanisms using KD mouse models, will facilitate the identification of metabolic signatures associated with disease severity, treatment response, and long-term cardiovascular outcomes. Targeting dysregulated metabolites or metabolic pathways may offer a promising approach for preventing coronary artery complications and improving the long-term cardiovascular prognosis of patients with KD. Supplementary The article’s supplementary files as